rebound pain
Conditions
Interventions
Butorphanol tartrate combined local anesthetic group:Brachial plexus block with 0.25% ropivacaine 20ml added with 1mg butorphanol tartrate and 1ml saline was given intravenously
Intravenous butorphanol tartrate group:Brachial plexus block was performed with 0.25% ropivacaine 20ml and butorphanol tartrate 1mg was given intravenously.
Control group:Brachial plexus block was performed with 0.25% ropivacaine 20ml and 1ml saline was given intravenously
Sponsors
First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients between 18 and 80 yr of age 2.Patients undergoing orthopaedic surgery of upper limb under general anesthesia combined with single brachial plexus block 3.ASA I ~ III
Exclusion criteria
Exclusion criteria: 1.Cognitive or mental dysfunction resulting in expected failure to comply with the study protocol 2.Presence of contraindications to the use of butorphanol tartrate or conventional postoperative analgesics 3.Peripheral nerve block injection site infection 4.Daily use of opioids > 2 weeks before surgery 5.Patients with peripheral neuropathy or injury and those with severe kidney, liver, or cardiovascular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of rebound pain;Quality of recovery; | — |
Secondary
| Measure | Time frame |
|---|---|
| rebound pain score;NRS-AUC;Duration of block;Time of first request for rescue pain medication;The use of postoperative pain medication;Adverse events occur; | — |
Countries
China
Contacts
Public ContactSun Defeng
First Affiliated Hospital of Dalian Medical University
Outcome results
None listed